Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.
IPO Year: n/a
Exchange: NYSE
Website: hillrom.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2021 | $148.00 → $156.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/8/2021 | Overweight → Sector Weight | Keybanc | |
| 9/3/2021 | $150.00 → $156.00 | Outperform → Neutral | Baird |
| 8/10/2021 | $130.00 | Buy → Neutral | B of A Securities |
| 8/10/2021 | Buy → Neutral | BofA Securities | |
| 8/2/2021 | $131.00 → $145.00 | Overweight | Keybanc |
CHICAGO, Nov. 5, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal fourth quarter and full-year ended September 30, 2021. For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.80 per diluted share, an increase of 27 percent compared to $0.63 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.67 per diluted share increased 43 percent and exceeded the company's previously-issued guidance range of $1.44 to $1.48 per diluted share. Adjustments to reported earnings are detail
CHICAGO, Nov. 2, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today that its board of directors declared a quarterly dividend of $0.24 per share payable on December 31, 2021, to shareholders of record as of the close of business on December 15, 2021. The indicated annual dividend rate is $0.96 per share. About HillromHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. They help
BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE:HRC) completed the acquisition of SV's portfolio company Bardy Diagnostics ("BDx"). In 2016, SV partnered with founder Dr. Gust Bardy to support the commercial launch of the Carnation Ambulatory Monitor, a best-in-class ambulatory cardiac monitor. The CAM offers both superior patient convenience and improved data capture. During the course of SV's partnership with BDx, the company built an increasingly sophisticated services capability and grew revenue ten-fold. SV wishes t
CHICAGO, July 30, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal third quarter ended June 30, 2021, and raised its full-year fiscal 2021 guidance. For the fiscal third quarter, Hillrom reported GAAP earnings of $0.74 per diluted share compared to $1.40 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.38 per diluted share exceeded the company's previously issued guidance range of $1.32 to $1.36 per diluted share. As previously disclosed, third quarter financial results reflect a d
CHICAGO, July 8, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today that its board of directors declared a fiscal 2021 fourth quarter dividend of $0.24 per share payable on September 30, 2021, to shareholders of record as of the close of business on September 17, 2021. The indicated annual dividend rate is $0.96 per share. About Hillrom Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients
CHICAGO, May 4, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today that its board of directors declared a fiscal 2021 third quarter dividend of $0.24 per share payable on June 30, 2021, to shareholders of record as of the close of business on June 18, 2021. The indicated annual dividend rate is $0.96 per share. About HillromHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. The
CHICAGO, March 11, 2021 /PRNewswire/ -- Hillrom (NYSE: HRC) announced today that its board of directors declared a 9 percent increase in the company's quarterly dividend rate, from the previous rate of $0.22 per share to $0.24 per share. The fiscal second quarter 2021 quarterly dividend is payable on March 31, 2021, to shareholders of record as of the close of business on March 22, 2021. The indicated annual dividend rate is $0.96 per share. "Hillrom is committed to returning value to our shareholders through our dividend while preserving financial flexibility for M&A and organic investments that further transform our portfolio and support our vision of Advancing Connected Care™," said Hillr
SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today the appointment of Amy Salzhauer and Greg Miller to the company's Board of Directors. Ms. Salzhauer currently serves as a Founder and Managing Partner at Good Growth Capital (GGC), an early-stage venture capital firm known for its exceptional expertise in finding, cultivating, and assessing complex science and technology start-ups based in Charleston, SC and Boston, MA. Mr. Miller recently retired as Executive Vice President and Chief Information Officer of Genuine Parts C
WAYNE, Pa.--(BUSINESS WIRE)--Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. She currently serves as a venture partner for Lightstone Ventures and since 2013 has a
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400: Alcoa Corp. (NYSE:AA) will replace Hill-Rom Holdings Inc. (NYSE:HRC) in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 20. S&P 500 constituent Baxter International Inc. (NYSE:BAX) is acquiring Hill-Rom in a deal that was completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector December 20, 2021 S&P MidCap 400 Addition Alcoa AA Materials S&P MidCap 400 Deletion Hill-Rom Holdings HRC Health Care For more
CHICAGO, Dec. 2, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced that its shareholders have voted to approve the previously announced pending acquisition by Baxter International Inc. (NYCE: BAX) at a special meeting. Hillrom shareholders voted overwhelmingly in favor of the transaction. Under the terms of the merger agreement, Hillrom shareholders will receive $156.00 per share in cash for every share of Hillrom stock they own immediately prior to the effective time of the merger. "The strong support of our investors over the years and in today's shareholder vote is an
CHICAGO, Nov. 5, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal fourth quarter and full-year ended September 30, 2021. For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.80 per diluted share, an increase of 27 percent compared to $0.63 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.67 per diluted share increased 43 percent and exceeded the company's previously-issued guidance range of $1.44 to $1.48 per diluted share. Adjustments to reported earnings are detail
CHICAGO, Nov. 2, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today that its board of directors declared a quarterly dividend of $0.24 per share payable on December 31, 2021, to shareholders of record as of the close of business on December 15, 2021. The indicated annual dividend rate is $0.96 per share. About HillromHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. They help
SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today the appointment of Amy Salzhauer and Greg Miller to the company's Board of Directors. Ms. Salzhauer currently serves as a Founder and Managing Partner at Good Growth Capital (GGC), an early-stage venture capital firm known for its exceptional expertise in finding, cultivating, and assessing complex science and technology start-ups based in Charleston, SC and Boston, MA. Mr. Miller recently retired as Executive Vice President and Chief Information Officer of Genuine Parts C
Transaction valued at $156.00 per Hillrom Share for an All-Cash Purchase Price of $10.5 Billion Brings together two leading medical technology companies to broaden access to care in the hospital, home and alternate site settings Accelerates digitally-enabled connected care solutions across the continuum of care Builds on Baxter's global footprint to expand Hillrom's penetration of international markets Creates significant opportunities to position Baxter for faster top- and bottom-line growth Expected to generate high single-digit ROIC by year five Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Hillrom (NYSE:HRC), a global medical technolo
BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE:HRC) completed the acquisition of SV's portfolio company Bardy Diagnostics ("BDx"). In 2016, SV partnered with founder Dr. Gust Bardy to support the commercial launch of the Carnation Ambulatory Monitor, a best-in-class ambulatory cardiac monitor. The CAM offers both superior patient convenience and improved data capture. During the course of SV's partnership with BDx, the company built an increasingly sophisticated services capability and grew revenue ten-fold. SV wishes t
CHICAGO, July 30, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal third quarter ended June 30, 2021, and raised its full-year fiscal 2021 guidance. For the fiscal third quarter, Hillrom reported GAAP earnings of $0.74 per diluted share compared to $1.40 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.38 per diluted share exceeded the company's previously issued guidance range of $1.32 to $1.36 per diluted share. As previously disclosed, third quarter financial results reflect a d
CHICAGO, July 20, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today it is Advancing Connected Care™ in the operating room (OR) with the launch of its Helion™ Integrated Surgical System in the U.S. market. The Helion System provides surgical teams with the operating room connectivity, flexibility and efficient staff communications they need to enhance patient outcomes. "The launch of the Helion System demonstrates our continued commitment to advancing Hillrom's connected care capabilities in the operating room," said Hillrom President and CEO John Groetelaars. "Our intui
CHICAGO, July 12, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced that the Delaware Court of Chancery ordered Hillrom to proceed with its proposed acquisition of Bardy Diagnostics, Inc. (BardyDx), denying Hillrom's claim of a Material Adverse Event under the terms of the acquisition agreement executed by the companies on January 15, 2021. HillromThe company intends to appeal this ruling to the Supreme Court of Delaware. Hillrom is assessing its strategic options in light of the Court's order and confirms that this decision does not have a material impact on the company's previously issued 2021 financial guidance.
15-12B - Hill-Rom Holdings, Inc. (0000047518) (Filer)
10-K/A - Hill-Rom Holdings, Inc. (0000047518) (Filer)
S-8 POS - Hill-Rom Holdings, Inc. (0000047518) (Filer)
S-8 POS - Hill-Rom Holdings, Inc. (0000047518) (Filer)
S-8 POS - Hill-Rom Holdings, Inc. (0000047518) (Filer)
S-8 POS - Hill-Rom Holdings, Inc. (0000047518) (Filer)
8-K - Hill-Rom Holdings, Inc. (0000047518) (Filer)
DEFA14A - Hill-Rom Holdings, Inc. (0000047518) (Filer)
8-K - Hill-Rom Holdings, Inc. (0000047518) (Filer)
10-K - Hill-Rom Holdings, Inc. (0000047518) (Filer)
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20211213-1447634/1447634_4hrc.pdf
Hillrom (NYSE:HRC) today announced that its shareholders have voted to approve the previously announced pending acquisition by Baxter International Inc. (NYCE: BAX) at a special meeting. Hillrom shareholders voted overwhelmingly in favor of the transaction. Under the terms of the merger agreement, Hillrom shareholders will receive $156.00 per share in cash for every share of Hillrom stock they own immediately prior to the effective time of the merger. "The strong support of our investors over the years and in today's shareholder vote is an important validation of our vision of Advancing Connected Care™, and we are proud of the significant shareholder value creation that has occurred due t
Morgan Stanley downgraded Hill-Rom Holdings from Overweight to Equal-Weight and set a new price target of $156.00 from $148.00 previously
Keybanc downgraded Hill-Rom Holdings from Overweight to Sector Weight
Baird downgraded Hill-Rom Holdings from Outperform to Neutral and set a new price target of $156.00 from $150.00 previously
B of A Securities downgraded Hill-Rom Holdings from Buy to Neutral and set a new price target of $130.00
BofA Securities downgraded Hill-Rom from Buy to Neutral
Keybanc reiterated coverage of Hill-Rom Holdings with a rating of Overweight and set a new price target of $145.00 from $131.00 previously
Baird reiterated coverage of Hill-Rom Holdings with a rating of Outperform and set a new price target of $125.00 from $115.00 previously
Raymond James reiterated coverage of Hill-Rom Holdings with a rating of Outperform and set a new price target of $122.00 from $120.00 previously
Raymond James reiterated coverage of Hill-Rom Holdings with a rating of Outperform and set a new price target of $120.00 from $113.00 previously
Baird reiterated coverage of Hill-Rom Holdings with a rating of Outperform and set a new price target of $115.00 from $105.00 previously